BioNTech SE
BNTXDrugs in Pipeline
44
Phase 3 Programs
20
Upcoming Catalysts
7
Next Catalyst
Mar 15, 2026
5wMarket Overview
Stock performance and market intelligence
7 upcoming, 0 past
BNT164a1 Phase 2 Results Expected
Primary completion for BNT164a1 trial (NCT05547464) in Tuberculosis
SourceBNT162b2 (2025/2026 recommended SARS-CoV-2 strain) Phase 3 Results Expected
Primary completion for BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) trial (NCT07069309) in COVID-19
SourceBivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose Phase 3 Results Expected
Primary completion for Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose trial (NCT05543616) in SARS-CoV-2 Virus
SourceBNT162b2 Vaccine Phase 3 Results Expected
Primary completion for BNT162b2 Vaccine trial (NCT07300839) in COVID-19
SourcePlacebo Phase 3 Results Expected
Primary completion for Placebo trial (NCT07300839) in COVID-19
SourceBNT162b2 (2025/2026 formulation) Phase 3 Results Expected
Primary completion for BNT162b2 (2025/2026 formulation) trial (NCT07222384) in COVID-19
SourceRO7198457 intravenous (IV) Phase 2 Results Expected
Primary completion for RO7198457 intravenous (IV) trial (NCT04486378) in Colorectal Cancer Stage II
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Pembrolizumab
Non-small Cell Lung Cancer
Biological/Vaccine: BNT162b2 10mcg
SARS-CoV-2 Infection, COVID-19
BNT162b2 OMI
SARS-CoV-2 Infection
BNT162b1
SARS-CoV-2 Infection
BNT162b2.B.1.351
SARS-CoV-2 Infection
BNT162b2 (Omi XBB.1.5)
SARS-CoV-2 Infection
BNT162b2 (Omi LP.8.1)
COVID-19
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
SARS-CoV-2 Virus
BNT162b5 Bivalent (WT/OMI BA.2)
SARS-CoV-2 Infection
Seasonal Inactivated Influenza Vaccine
SARS-CoV-2 Infection
BNT113
Unresectable Head and Neck Squamous Cell Carcinoma
Influenza and COVID-19 Combination A
Influenza
Investigational Influenza Vaccine
Influenza,Human
BNT162b2 Vaccine
COVID-19
BNT162b2
SARS-CoV-2 Infection
BNT162b2 (2025/2026 formulation)
COVID-19
Carboplatin
Extensive-stage Small-cell Lung Cancer
Paclitaxel
Endometrial Cancer
Gemcitabine
Breast Neoplasms
Pumitamig
Extensive-stage Small-cell Lung Cancer
BNT164a1
Tuberculosis
BNT327 Dose Level 1 (DL2)
Locally Advanced Breast Cancer
Nab-paclitaxel
Pancreatic Ductal Adenocarcinoma (PDAC)
Roxadustat
Chronic Kidney Disease
Temozolomide
Recurrent Glioblastoma
Docetaxel
Non-small Cell Lung Cancer
BNT329
Advanced Solid Cancers
BNT326
Advanced Solid Tumor
BNT162b3
Covid-19
BNT111
Melanoma Stage III
BNT314
Metastatic Colorectal Cancer
bivalent BNT162b2 (original/Omi BA.4/BA.5)
Influenza, Human
BNT162b2s01
COVID-19
BNT327
Non-small Cell Lung Cancer
BNT142
Solid Tumor
BNT3212
Advanced Solid Tumor
RO7198457 intravenous (IV)
Colorectal Cancer Stage II
BNT324
Advanced Lung Cancer
BNT166a
Monkeypox
BNT323
Locally Advanced Breast Cancer
Investigational COVID-19 Vaccine
Influenza
BNT165e
Malaria
BNT162a1
Infections, Respiratory
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
SARS-CoV-2 Infection
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Pembrolizumab | Phase 3 | Non-small Cell Lung Cancer | - |
Biological/Vaccine: BNT162b2 10mcg | Phase 3 | SARS-CoV-2 Infection, COVID-19 | - |
BNT162b2 OMI | Phase 3 | SARS-CoV-2 Infection | - |
BNT162b1 | Phase 3 | SARS-CoV-2 Infection | - |
BNT162b2.B.1.351 | Phase 3 | SARS-CoV-2 Infection | - |
BNT162b2 (Omi XBB.1.5) | Phase 3 | SARS-CoV-2 Infection | - |
BNT162b2 (Omi LP.8.1) | Phase 3 | COVID-19 | - |
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | Phase 3 | SARS-CoV-2 Virus | - |
BNT162b5 Bivalent (WT/OMI BA.2) | Phase 3 | SARS-CoV-2 Infection | - |
Seasonal Inactivated Influenza Vaccine | Phase 3 | SARS-CoV-2 Infection | - |
BNT113 | Phase 3 | Unresectable Head and Neck Squamous Cell Carcinoma | - |
Influenza and COVID-19 Combination A | Phase 3 | Influenza | - |
Investigational Influenza Vaccine | Phase 3 | Influenza,Human | - |
BNT162b2 Vaccine | Phase 3 | COVID-19 | - |
BNT162b2 | Phase 3 | SARS-CoV-2 Infection | - |
BNT162b2 (2025/2026 formulation) | Phase 3 | COVID-19 | - |
Carboplatin | Phase 3 | Extensive-stage Small-cell Lung Cancer | - |
Paclitaxel | Phase 3 | Endometrial Cancer | - |
Gemcitabine | Phase 3 | Breast Neoplasms | - |
Pumitamig | Phase 3 | Extensive-stage Small-cell Lung Cancer | - |
BNT164a1 | Phase 2 | Tuberculosis | - |
BNT327 Dose Level 1 (DL2) | Phase 2 | Locally Advanced Breast Cancer | - |
Nab-paclitaxel | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - |
Roxadustat | Phase 2 | Chronic Kidney Disease | - |
Temozolomide | Phase 2 | Recurrent Glioblastoma | - |
Docetaxel | Phase 2 | Non-small Cell Lung Cancer | - |
BNT329 | Phase 2 | Advanced Solid Cancers | - |
BNT326 | Phase 2 | Advanced Solid Tumor | - |
BNT162b3 | Phase 2 | Covid-19 | - |
BNT111 | Phase 2 | Melanoma Stage III | - |
BNT314 | Phase 2 | Metastatic Colorectal Cancer | - |
bivalent BNT162b2 (original/Omi BA.4/BA.5) | Phase 2 | Influenza, Human | - |
BNT162b2s01 | Phase 2 | COVID-19 | - |
BNT327 | Phase 2 | Non-small Cell Lung Cancer | - |
BNT142 | Phase 2 | Solid Tumor | - |
BNT3212 | Phase 2 | Advanced Solid Tumor | - |
RO7198457 intravenous (IV) | Phase 2 | Colorectal Cancer Stage II | - |
BNT324 | Phase 2 | Advanced Lung Cancer | - |
BNT166a | Phase 2 | Monkeypox | - |
BNT323 | Phase 2 | Locally Advanced Breast Cancer | - |
Investigational COVID-19 Vaccine | Phase 2 | Influenza | - |
BNT165e | Phase 2 | Malaria | - |
BNT162a1 | Phase 2 | Infections, Respiratory | - |
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2) | Phase 2 | SARS-CoV-2 Infection | - |
Regulatory & News
Approvals, filings, and latest developments